Mission Bio
Latest round
- Series C
Last raised
- Jul 2020
Total raised
- $122M
Investors
- 15
About Mission Bio
Based in the US, Mission Bio, Inc.Mission Bio, Inc. was founded in 2014 and is headquartered in San Francisco, US.00 mn on June 1, 2022, from Armentum Partners.Mission Bio specializes in single-cell technology that enhances the development of cell therapies and provides detailed insights into cancer mechanisms. Their core product, the Tapestri Single-cell Multiomics Solution, allows researchers to analyze single nucleotide variation (SNV), copy number variation (CNV), and protein data from individual cells, particularly in the context of diseases like multiple myeloma. This platform addresses critical research needs by revealing clonal heterogeneity, which plays a significant role in disease progression and treatment responses. Mission Bio primarily serves cancer researchers and pharmaceutical companies involved in drug development and clinical research, offering end-to-end support from initial studies to commercial manufacturing and release testing.Mission Bio generates revenue through a combination of direct sales and partnerships with pharmaceutical companies and research institutions. Their business model involves subscriptions for access to their technology, alongside transactional sales of the Tapestri platform and related services. Clients typically engage in long-term collaborations that include the procurement of single-cell technology for specific research projects or drug development initiatives. The revenue structure is supported by agreements that facilitate the delivery of ongoing support and assay development services tailored to the unique needs of each client.In the coming years, Mission Bio plans to expand its product offerings with new innovations in single-cell technology aimed at enhancing precision medicine solutions.00 mn will be utilized to accelerate product development and support market entry into new regions, specifically targeting expansion in Europe and Asia by the end of 2023. This initiative is expected to strengthen the company's presence in vital biotech hubs and foster collaborations with more pharmaceutical partners.
Who invested in Mission Bio
15 investors across 5 rounds
See all investors in Mission Bio
Sign up free to see every VC on the cap table, the rounds they joined, and how much each round raised.
Questions about Mission Bio
Who invested in Mission Bio?
Mission Bio has 15 investors on record across 5 venture rounds. Sign up free to see every VC on the cap table and the rounds they joined.
How much funding has Mission Bio raised?
Mission Bio has raised 5 venture rounds. Sign up free to see how much each round raised and the total.
When did Mission Bio last raise money?
Mission Bio's most recent round on record is a Series C, in Jul 2020.
What does Mission Bio do?
Based in the US, Mission Bio, Inc.
Where is Mission Bio headquartered?
Mission Bio is headquartered in San Francisco, US.
Which VCs invest in companies like Mission Bio?
Among active investors with capital left to deploy, Andreessen Horowitz, Founders Fund, Accel and Thrive Capital back biotechnology companies at Mission Bio's stage. Their profiles are linked below.
VCs backing biotechnology startups at Series C
Raising like Mission Bio? Find the right VCs.
Capital Atlas matches your startup to active investors by stage, sector and region.